Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | ATM | Q13315 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.67 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687327 | 1.00 | HPGD (1.00) | HPGDKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL30678539 | 1.00 | HPGD (1.00) | HPGDKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL30914546 | 0.92 | HPGD (0.85) | HPGDKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL6570578 | 0.87 | KMT2A (0.88) | HPGDKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL23412465 | 0.86 | KMT2A (0.78) | HPGDKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL30093073 | 0.86 | KMT2A (0.78) | HPGDKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL763451 | 0.85 | KMT2A (0.86) | HPGDKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL11918653 | 0.85 | KMT2A (0.86) | HPGDKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL3034740 | 0.85 | KMT2A (0.81) | HPGDKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL279957 | 0.85 | KMT2A (0.86) | HPGDKMT2AMEN1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2850071-A1 | ISOINDOLONE DERIVATIVES | AbbVie Inc. (US) | 2015-03-25 | — | — | EP | claimed |
| EP-2838881-A1 | ISOINDOLONE DERIVATIVES | AbbVie Inc. (US) | 2015-02-25 | — | — | EP | claimed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | claimed |
| WO-2013158952-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. (US) | 2013-10-24 | — | — | WO | claimed |
| WO-2013155695-A1 | ISOINDOLONE DERIVATIVES | ABBOTT LABORATORIES (US) | 2013-10-24 | — | — | WO | claimed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | claimed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | claimed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | claimed |
| JP-2006528597-A | — | — | 2006-12-21 | — | — | JP | claimed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | claimed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | claimed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | claimed |
| US-12060339-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | VIVOZON INC. (KR) | 2024-08-13 | — | — | US | disclosed |
| US-20240092790-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-21 | — | — | US | disclosed |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | SIERRA ONCOLOGY, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2004026816-A1 | AROMATIC LIVER X-RECEPTOR MODULATORS | PHARMACIA CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-0483714-B1 | A method of preparing an acid additional salt of delta-aminolevulinic acid | JAPAN TOBACCO INC (JP) | 1995-05-03 | — | — | EP | disclosed |
| US-5284973-A | Method of preparing an acid additional salt of delta-aminolevulinic acid | JAPAN TOBACCO INC. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0483714-A1 | A method of preparing an acid additional salt of delta-aminolevulinic acid | Japan Tobacco Inc. (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | PIM1, PIM2, PIM3 | HPGD 2939/4885KMT2A 1421/4885MEN1 3946/4885 |
| US-12060339-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | GRM5, HTR5A, HTR2A | HPGD 1388/4885KMT2A 959/4885MEN1 4816/4885 |
| US-20240092790-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | HPGD 61/4885KMT2A 3061/4885MEN1 4234/4885 |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | JAK2, JAK1, JAK3 | HPGD 1481/4885KMT2A 835/4885MEN1 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.